R. Chiron

发表

Impact of Rhinitis on Asthma Control in Children: Association With FeNO

P. Chanez, I. Vachier, P. Godard, 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

Biofilm Formation in Methicillin-Resistant Staphylococcus aureus Isolated in Cystic Fibrosis Patients Is Strain-Dependent and Differentially Influenced by Antibiotics

C. Dunyach-Rémy, J. Lavigne, C. Pouget, 2021, Frontiers in Microbiology.

Long‐term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis

A. Chuchalin, H. Cicirello, C. Geidel, 2014, Pediatric pulmonology.

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

S. Lewis, R. Fischer, N. McElvaney, 2013, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

M. Konstan, P. Flume, M. Kappler, 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.

M. Humbert, A. Didier, P. Berger, 2012, Chest.

Biologics in asthma: difficulties and drawbacks

J. Bousquet, M. Humbert, R. Chiron, 2008 .

A model for active and healthy ageing with a rare genetic disease: cystic fibrosis

J. Bousquet, P. Demoly, D. Caimmi, 2016, European Respiratory Journal.

Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study.

L. Meijer, S. Leroy, S. Hillion, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients.

I. Pin, J. Gaillard, J. Herrmann, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Mycobacterium chimaera Pulmonary Disease in Cystic Fibrosis Patients, France, 2010–2017

K. Klouche, S. Godreuil, C. Carrière, 2019, Emerging infectious diseases.

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients

D. Caimmi, S. Godreuil, R. Chiron, 2018, Open forum infectious diseases.

MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

Rosalind W. Picard, D. Ryan, A. Sheikh, 2018, Clinical and Translational Allergy.

A new perspective on opportunistic pathogens of the genus Bordetella in cystic fibrosis.

F. Aujoulat, E. Jumas‐Bilak, H. Marchandin, 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Intrapatient diversity of Achromobacter spp. involved in chronic colonization of Cystic Fibrosis airways.

N. nørskov-lauritsen, E. Jumas‐Bilak, H. Marchandin, 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Gluconobacter as Well as Asaia Species, Newly Emerging Opportunistic Human Pathogens among Acetic Acid Bacteria

A. Lozniewski, E. Jumas‐Bilak, C. Teyssier, 2010, Journal of Clinical Microbiology.

Clinical and Microbiological Features of Inquilinus sp. Isolates from Five Patients with Cystic Fibrosis

G. Bellon, D. Turck, F. Brémont, 2005, Journal of Clinical Microbiology.

Sacroiliitis secondary to catheter-related bacteremia due to Mycobacterium abscessus (sensu stricto)

S. Godreuil, A. Bañuls, H. Jean-Pierre, 2014, Annals of Clinical Microbiology and Antimicrobials.

Evaluation of the GenoType NTM-DR assay performance for the identification and molecular detection of antibiotic resistance in Mycobacterium abscessus complex

S. Godreuil, A. Bañuls, H. Guet-Revillet, 2020, PloS one.

[National consensus regarding azithromycin use in cystic fibrosis].

M. Abély, M. Fayon, S. Bui, 2015, Revue des maladies respiratoires.

A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients

F. Vandenesch, P. Reix, I. Durieu, 2015, Medical Microbiology and Immunology.

Advances toward the Elucidation of Hypertonic Saline Effects on Pseudomonas aeruginosa from Cystic Fibrosis Patients

B. Lamy, E. Jumas‐Bilak, H. Marchandin, 2014, PloS one.

Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics

P. Bousquet, P. Demoly, D. Caimmi, 2012, Clinical and Translational Allergy.

Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study

J. Emile, R. Epaud, H. Ducou le Pointe, 2020, Orphanet Journal of Rare Diseases.

New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare(R) cohort

P. Reix, R. Epaud, A. Clément, 2018 .

New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespiRare® cohort

P. Reix, R. Epaud, A. Clément, 2013, Orphanet Journal of Rare Diseases.

AGER -429T/C Is Associated with an Increased Lung Disease Severity in Cystic Fibrosis

P. Böelle, P. Reix, J. Dalphin, 2012, PloS one.

Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease

W. Hoefsloot, J. Altenburg, E. Haarman, 2022, Chest.

Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study

N. Veziris, C. Emery, S. Bouée, 2021, BMC Infectious Diseases.

MACVIA-LR, Reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) in Languedoc Roussillon

J. Robine, B. Bardy, P. Courtet, 2014 .

LXA4 stimulates ZO-1 expression and transepithelial electrical resistance in human airway epithelial (16HBE14o-) cells.

R. Chiron, V. Urbach, Y. Grumbach, 2009, American journal of physiology. Lung cellular and molecular physiology.

LXA 4 stimulates ZO-1 expression and transepithelial electrical resistance in human airway epithelial ( 16 HBE 14 o-) cells

R. Chiron, V. Urbach, Y. Grumbach, 2008 .

Effectiveness of bacteriophages in the sputum of cystic fibrosis patients.

I. Vachier, N. Molinari, I. Sermet, 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Intragenomic and intraspecific heterogeneity of the 16S rRNA gene in seven bacterial species from the respiratory tract of cystic fibrosis patients assessed by PCR-Temporal Temperature Gel Electrophoresis.

E. Jumas‐Bilak, H. Marchandin, R. Chiron, 2012, Pathologie-biologie.

Lipoxin A(4) and interleukin-8 levels in cystic fibrosis sputum after antibiotherapy.

R. Chiron, V. Urbach, Y. Grumbach, 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

In-Host Emergence of Linezolid Resistance in a Complex Pattern of Toxic Shock Syndrome Toxin-1-Positive Methicillin-Resistant Staphylococcus aureus Colonization in Siblings with Cystic Fibrosis

C. Dunyach-Rémy, J. Lavigne, H. Marchandin, 2021, Toxins.

Utility of the Etest GRD for detecting Staphylococcus aureus with reduced susceptibility to glycopeptides in cystic fibrosis patients

M. Reverdy, E. Jumas‐Bilak, H. Jean-Pierre, 2012, European Journal of Clinical Microbiology & Infectious Diseases.

Biologics in asthma: difficulties and drawbacks.

J. Bousquet, M. Humbert, R. Chiron, 2008, Expert opinion on biological therapy.

Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization

J. Benichou, P. Reix, I. Pin, 2021, Pulmonary Therapy.

Cumulative Incidence and Risk Factors for Severe COVID-19 in French People with Cystic Fibrosis

P. Reix, P. Burgel, C. Marguet, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.

P. Reix, P. Burgel, J. Paillasseur, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A Randomized-Controlled Trial Of Omalizumab In Patients With Severe Difficult To Control Nonatopic Asthma

M. Humbert, A. Didier, P. Berger, 2012, ATS 2012.

Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.

S. Leroy, P. Burgel, J. Paillasseur, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study

S. Chevret, B. Wallaert, D. Valeyre, 2015, Orphanet Journal of Rare Diseases.

CFTR p.Arg117His associated with CBAVD and other CFTR-related disorders

A. Valéri, C. Clavel, G. Karsenty, 2013, Journal of Medical Genetics.

Highly Diversified Pandoraea pulmonicola Population during Chronic Colonization in Cystic Fibrosis

F. Aujoulat, E. Jumas‐Bilak, H. Marchandin, 2017, Front. Microbiol..

Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing

E. Jumas‐Bilak, H. Marchandin, R. Chiron, 2016, Journal of Clinical Microbiology.

Early follow‐up of lung disease in infants with cystic fibrosis using the raised volume rapid thoracic compression technique and computed tomography during quiet breathing

S. Matecki, M. Giroux-Metgès, N. Molinari, 2017, Pediatric pulmonology.

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

C. Goss, H. Rodgers, P. Burgel, 2020, Journal of Cystic Fibrosis.

patients who report a history suggestive of drug allergy to beta-lactam antibiotics

P. Bousquet, P. Demoly, D. Caimmi, 2012 .

High Occurrence of Bacterial Competition Among Clinically Documented Opportunistic Pathogens Including Achromobacter xylosoxidans in Cystic Fibrosis

E. Jumas‐Bilak, H. Marchandin, R. Chiron, 2020, Frontiers in Microbiology.

Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.

D. Caimmi, A. Didier, S. Leroy, 2020, American journal of respiratory and critical care medicine.

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.

S. Leroy, P. Burgel, D. Grenet, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Quick and wide-range taxonomical repertoire establishment of the cystic fibrosis lung microbiota by tandem mass spectrometry on sputum samples

J. Armengaud, O. Pible, Karen Culotta, 2022, Frontiers in Microbiology.

First Wave of COVID-19 in French Patients with Cystic Fibrosis

P. Boelle, P. Burgel, L. Guillot, 2020, Journal of clinical medicine.

[National consensus regarding the prescription of inhaled corticosteroids in cystic fibrosis].

H. Corvol, S. Bui, R. Chiron, 2014, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

Gluconobacter as Well as Asaia Species, Newly Emerging Opportunistic Human Pathogens among Acetic Acid Bacteria

A. Lozniewski, E. Jumas‐Bilak, C. Teyssier, 2011, Journal of Clinical Microbiology.

Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis

Nicolas Molinari, Anne Bergougnoux, Mireille Claustres, 2014, European Respiratory Journal.

Lipoxin A4 Stimulates Calcium-Activated Chloride Currents and Increases Airway Surface Liquid Height in Normal and Cystic Fibrosis Airway Epithelia

B. Harvey, R. Costello, R. Chiron, 2012, PloS one.

Dynamic changes of DNA methylation and lung disease in cystic fibrosis: lessons from a monogenic disease.

D. Caimmi, S. Leroy, M. Claustres, 2018, Epigenomics.

DNA methylation at modifier genes of lung disease severity is altered in cystic fibrosis

D. Caimmi, S. Leroy, L. Guillot, 2017, Clinical Epigenetics.

MACVIA‐ARIA Sentinel NetworK for allergic rhinitis (MASK‐rhinitis): the new generation guideline implementation

F. Rodenas, G. Joos, R. Bourret, 2015, Allergy.

Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

A. Sheikh, O. Mayora, T. To, 2019, Clinical and Translational Allergy.

Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology.

A. Sheikh, O. Mayora, T. To, 2019, The Journal of allergy and clinical immunology.

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

Todor A Popov, D. Postma, A. Sheikh, 2016, Clinical and Translational Allergy.

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

D. Postma, I. Pavord, A. Sheikh, 2016, Clinical and Translational Allergy.

Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

G. Fico, P. Siciliano, M. Kovac, 2016, The journal of nutrition, health & aging.

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

D. Postma, I. Pavord, A. Sheikh, 2014, European Respiratory Journal.

Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.

I. Durieu, L. Kessler, S. Touzet, 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A national internet-linked based database for pediatric interstitial lung diseases: the French network

C. Delacourt, J. Vibert, P. Reix, 2012, Orphanet Journal of Rare Diseases.

Should diffuse bronchiectasis still be considered a CFTR-related disorder?

M. Claustres, N. Molinari, M. Taulan-Cadars, 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Extrathoracic investigation in adult patients with isolated pulmonary langerhans cell histiocytosis

L. Vercellino, S. Chevret, B. Wallaert, 2016, Orphanet Journal of Rare Diseases.

Ochrobactrum and Agrobacterium spp.: emerging opportunistic pathogens in cystic fibrosis patients?

E. Jumas‐Bilak, C. Teyssier, H. Marchandin, 2009 .

Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients’ Lung

E. Jumas‐Bilak, H. Marchandin, R. Chiron, 2021, Genes.

Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.

P. Burgel, J. Paillasseur, I. Durieu, 2021, American journal of respiratory and critical care medicine.

Blood co-expression modules identify potential modifier genes of diabetes and lung function in cystic fibrosis

D. Caimmi, S. Leroy, M. Claustres, 2020, PloS one.

The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant

P. Burgel, I. Durieu, I. Sermet-Gaudelus, 2023, European Respiratory Journal.

Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor–ivacaftor in people with cystic fibrosis

M. Revel, P. Reix, P. Burgel, 2021, European Respiratory Journal.

Streptococcus pseudopneumoniae, an opportunistic pathogen in patients with cystic fibrosis.

H. Marchandin, R. Chiron, Marion Normandin, 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment

F. Aujoulat, E. Jumas‐Bilak, H. Marchandin, 2018, Applied and Environmental Microbiology.

Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study

H. Guet-Revillet, C. Segonds, S. Bui, 2020, BMC Pulmonary Medicine.

Estimation of the radiation dose from thoracic CT scans in a cystic fibrosis population.

C. Roudier, J. Donadieu, Jean Donadieu, 2007, Chest.

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience

D. Caimmi, L. Kremer, W. Hoefsloot, 2022, Open forum infectious diseases.

Factors associated with asthma severity in children: data from the French COBRAPed Cohort.

P. Reix, P. Berger, I. Pin, 2020, The journal of allergy and clinical immunology. In practice.

Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)

D. Postma, I. Pavord, A. Sheikh, 2017, Clinical and Translational Allergy.

42 Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial

G. Bader, M. Konstan, G. Angyalosi, 2014 .

69 Efficacy on lung function and safety of multiple courses of tobramycin 300mg/4mL nebuliser solution (Bramitob) in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection: results from a 48-week extension phase

H. Cicirello, R. Chiron, H. Mazurek, 2012 .

111 Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection: results in different age subgroups

A. Chuchalin, H. Cicirello, C. Geidel, 2011 .

Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores.

N. Paragios, M. Revel, E. Zacharaki, 2020, Radiology. Cardiothoracic imaging.

DNA Methylation at ATP11A cg11702988 Is a Biomarker of Lung Disease Severity in Cystic Fibrosis: A Longitudinal Study

D. Caimmi, M. Claustres, S. Taviaux, 2021, Genes.

Metaproteomics to Decipher CF Host-Microbiota Interactions: Overview, Challenges and Future Perspectives

J. Armengaud, H. Marchandin, L. Grenga, 2021, Genes.

Biofilm Formation by Staphylococcus aureus in the Specific Context of Cystic Fibrosis

J. Lavigne, H. Marchandin, R. Chiron, 2022, International journal of molecular sciences.

Staphylococcus aureus with decreased susceptibility to glycopeptides in cystic fibrosis patients.

M. Reverdy, E. Jumas‐Bilak, H. Jean-Pierre, 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A simplified, semi-quantitative structural lung disease computed tomography outcome during quiet breathing in infants with cystic fibrosis.

S. Matecki, P. Reix, N. Molinari, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Management of initial colonisations with Burkholderia species in France, a retrospective analysis in five Cystic Fibrosis Centres

H. Guet-Revillet, C. Segonds, S. Bui, 2019 .

The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis.

M. Claustres, I. Vachier, N. Molinari, 2017, The international journal of biochemistry & cell biology.

P265 Real-life initiation of lumacaftor/ivacaftor in adolescents and adults homozygous for the F508del CFTR mutation: a French nationwide study

P. Reix, P. Burgel, I. Durieu, 2019, Journal of Cystic Fibrosis.

Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children.

B. Kerem, P. Reix, P. Burgel, 2023, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

49 Lumacaftor/ivacaftor (LUM/IVA) treatment in patients (pts) with cystic fibrosis (CF) aged ≥12 years homozygous for F508del-CFTR: description of a French Temporary Authorization for Use (ATU) cohort

P. Reix, P. Kiefer, R. Chiron, 2017 .

Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement

D. Ryan, R. Picard, M. Kogevinas, 2017, Allergy.

Sacroiliitis secondary to catheter-related bacteremia due to Mycobacterium abscessus (sensu stricto)

S. Godreuil, A. Bañuls, H. Jean-Pierre, 2014, Annals of Clinical Microbiology and Antimicrobials.

Rhinovirus‐associated pulmonary exacerbations show a lack of FEV 1 improvement in children with cystic fibrosis

D. Caimmi, I. Vachier, N. Molinari, 2016, Influenza and other respiratory viruses.

MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis.

Todor A Popov, I. Pavord, A. Sheikh, 2016, The Journal of allergy and clinical immunology.

A balance between activating and repressive histone modifications regulates cystic fibrosis transmembrane conductance regulator (CFTR) expression in vivo

M. Claustres, J. Varilh, C. Raynal, 2014, Epigenetics.

Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

D. Postma, J. Robine, M. Barbagallo, 2017, The journal of nutrition, health & aging.

European Innovation Partnership on Active and Healthy Ageing, Action Plan B3 Mechanisms of the Development of Allergy (MeDALL, WP10) GARD (Global Alliance against Chronic Respiratory Diseases, WHO) research demonstration project

S. Bonini, T. Haahtela, O. Kalayci, 2014 .

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation.

Todor A Popov, D. Postma, R. Picard, 2015, Allergy.

Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

O. Mayora, T. To, D. Caillaud, 2019, Clinical and Translational Allergy.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

M. Konstan, P. Flume, M. Kappler, 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

C. Goss, H. Rodgers, P. Burgel, 2022, Journal of Cystic Fibrosis.

[The reference site of the European Innovation Partnership on Active and Healthy Aging MACVIA-LR (the fight against chronic diseases for an active and healthy aging in Languedoc-Roussillon)].

P. Claret, J. Robine, B. Bardy, 2015, Presse medicale.

Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease.

S. Leroy, P. Burgel, D. Grenet, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Highly diverse dynamics of Pseudomonas aeruginosa colonization from initial detection in cystic fibrosis patients: A 7-year longitudinal genetic diversity study.

F. Aujoulat, E. Jumas‐Bilak, H. Marchandin, 2023, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.